<DOC>
	<DOCNO>NCT01625026</DOCNO>
	<brief_summary>By bind nuclear receptor FXR , bile acid regulate turn-over presumably also pivotal step cholesterol , triglyceride glucose metabolism show laboratory animal . Obeticholic acid ( OCA ) semisynthetic bile acid high affinity FXR . In pharmacodynamic study effect OCA bile acid , lipid glucose turn-over study 20 morbidly obese 20 gallstone patent , respectively , administer OCA 25 mg/day three week bariatric ( BS ) gallstone ( GS ) surgery addition blood sample also biopsies take liver case BS , omental subcutaneous adipose tissue case GS , gallbladder bile .</brief_summary>
	<brief_title>Obeticholic Acid Bariatric Gallstone Disease</brief_title>
	<detailed_description>In placebo-controlled double-blind randomize trial , 20 otherwise healthy morbidly obese patient schedule bariatric surgery , 20 otherwise healthy gallstone patient administer 25 mg/day INT-747 placebo three week day surgery . Serum day 1 21 analyzed routine liver test , bile acid , complete lipid profile include FA addition 7α-hydroxy-4-cholesten-3-one FGF-19 , marker bile acid synthesis intestinal stimulation . For evaluation insulin resistance possible pre-diabetes , plasma take estimation HOMA index oral glucose tolerance test ( OGTT ) perform day 1 21 . At surgery , liver biopsy ( 0.5-1 g ) white adipose tissue ( WAT ) specimen ( 1 cm2 ) take immediately frozen liquid nitrogen mRNA protein preparation quantitative RT-PCR Western analysis , respectively , histopathological NAFLD grading , measure hepatic WAT lipase activity . In gallstone patient , gallbladder bile sample measurement biliary lipid ( cholesterol , phospholipid , bile acid ) calculation cholesterol saturation index .</detailed_description>
	<mesh_term>Gallstones</mesh_term>
	<mesh_term>Cholelithiasis</mesh_term>
	<mesh_term>Cholecystolithiasis</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>In obesity group : BMI ≥35 kg/m2 In gallstone group : symptomatic , ultrasound verify gallstone disease Chronic liver disease NAFLD ( viral hepatitis , autoimmune liver disease , hemochromatosis , homozygous alpha1antitrypsin deficiency Wilson disease ) Previous gastric small bowel surgery Inflammatory bowel disease Uncontrolled diabetes mellitus ( fast blood glucose &gt; 6.7 mmol/L ) , hypothyroidism hyperthyroidism , significant endocrine disease . Pregnancy . A urine pregnancy test perform day start medication . Women childbearing potential include safe reliable contraception use , e.g. , oral contraceptive . Elevations transaminase ( ALAT/ASAT ) alkaline phosphatase bilirubin 2xULN ( upper limit normal ) day start medication . Other serious disease , include depressive disorder treat medication Patients comply protocol . A subject euthyroid stable replacement dose thyroid hormone acceptable provide TSH within normal range .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Morbidly obesity</keyword>
	<keyword>Gastric bypass</keyword>
	<keyword>Cholecystolithiasis</keyword>
</DOC>